Aytu Biopharma (AYTU) Change in Accured Expenses (2010 - 2026)
Aytu Biopharma (AYTU) posted quarterly Change in Accured Expenses of -$5.9 million for Q1 2026, down 466.27% year-over-year from $1.6 million in Q1 2025, and down 270.31% quarter-over-quarter from $3.5 million in Q4 2025.
Aytu Biopharma (AYTU) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Change in Accured Expenses for 17 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 466.27% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$7.1 million (down 291.06% YoY), while the FY2025 annual figure was $886000.0, up 109.67% from the prior year.
- Change in Accured Expenses declined to -$5.9 million in Q1 2026 per AYTU's latest filing, from $3.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.0 million in Q1 2023 and bottomed at -$14.5 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged -$1.3 million across 5 years, with a median of -$1.6 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 574.67% — and 2025, when it soared 879.88%.
- Aytu Biopharma's Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 48.52% to $1.3 million in 2023, then soared by 474.23% to $7.3 million in 2024, then sank by 52.72% to $3.5 million in 2025, then slumped by 270.31% to -$5.9 million in 2026.
- Business Quant data shows AYTU's Change in Accured Expenses at -$5.9 million in Q1 2026, $3.5 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Aytu Biopharma | 24.70 Mn | -2.01 Mn | 7.60 Mn | -5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.89 Mn |
| Mar 31, 2026 | -5.89 Mn |
| Dec 31, 2025 | 3.46 Mn |
| Dec 31, 2025 | 3.46 Mn |
| Sep 30, 2025 | -1.64 Mn |
| Sep 30, 2025 | -1.64 Mn |
| Jun 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | -3.06 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 7.31 Mn |
| Dec 31, 2024 | 7.31 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | 164,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Dec 31, 2023 | 1.27 Mn |
| Dec 31, 2023 | 1.27 Mn |